# A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SRK-001 in Healthy Participants

> **NCT05156034** · PHASE1 · TERMINATED · sponsor: **Sarkana Pharma Inc** · enrollment: 16 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** SRK-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05156034
- **Lead sponsor:** Sarkana Pharma Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-21
- **Primary completion:** 2022-09-05
- **Final completion:** 2022-09-05
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Due to occurrence of eye related adverse events.
- **Last updated:** 2023-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156034, "A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SRK-001 in Healthy Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05156034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*